Powered by

Big Pharma: Covington and Cooley dominate hot deals market

Feb 08, 2016 - The Lawyer

Worldwide deals worth $220bn in just18 months show what Big Pharma will pay to gain an R&D edge, and it's primarily US law firms injecting the advisory boost

The pharmaceutical sector has seen a lot of deal activity in the past 18 months, with large drug companies acquiring their smaller, more nimble and often more innovative counterparts.

Part of the motivation behind this wave of acquisitions, worth a combined $220bn (£152bn) in the first half of 2015, is access to crucial R&D int...